Figure 2.

Patient-reported elements of the prostate cancer screening discussion in relation to the Merenstein case (N = 432).

PSA = prostate-specific antigen.

Note: The figure shows temporal trends of measured elements of the prostate cancer screening process in relation to the Merenstein case (before, diffusion, and after periods) as reported by 432 patients who returned a completed questionnaire. The left-hand axis and black lines represent an ordinal scale from 1 to 10. The right-hand axis and gray lines represent a percentage scale from 0% to 100%. Comparing the before and after time periods, the differences are not significant for decisional conflict (P = .23), number of topics discussed (P = .37), time spent on discussion (P = .20), and knowledge (P = .86). The percentage of patients receiving a PSA test increased, however (84% vs 90%; P = .03).